Log In
Print this Print this

subcutaneous Factor VIIa-CTP (subcutaneous MOD-5014)

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionLong-acting recombinant Factor VIIa developed using carboxyl terminal peptide (CTP) technology
Molecular Target Factor VIIa
Mechanism of ActionCoagulant
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationHemophilia
Indication DetailsTreat bleeding episodes in patients with hemophilia A or B with inhibitors to Factor VIII or Factor IX
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today